The green light means that Keytruda is muscling in on territory held by GlaxoSmithKline's rival drug Jemperli (dostarlimab), which was approved for patients with recurrent or advanced endometrial ...
The drugmaker remains convinced of the potential of the drug, however, and has just reported results of a trial comparing Jemperli (dostarlimab) to Merck & Co's market-leading Keytruda ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback